Rigel Pharmaceuticals, Incorporated

Vadim Markovtsov

Rajinder Paul Singh

Sambaiah Thota

Hui Li

Somasekhar Bhamidipati

Vanessa Taylor

David Carroll

Ankush Argade

Jeffrey Clough

Kin Tso

Robin Cooper

Andy Atuegbu

Holger Keim

John McLaughlin

Yasumichi Hitoshi

John Yudhistir Ramphal

Esteban Masuda

Jiaxin Yu

Ihab S Darwish

Pingyu Ding

Arvinder Sran

Hui Hong

Avinder Sran

Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.

Method for treatment of COVID-19-associated conditions

The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.

Cycloalkyl substituted pyrimidinediamine compounds and their uses

This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R, R, R, Rand Rare disclosed herein, or a pharmaceutically acceptable salt.

Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.

Whole blood assay for measuring AMPK activation

The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful.

Tricyclic carbamate JAK inhibitors

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

Growing community of inventors

San Mateo, CA, United States of America

Vadim Markovtsov